Novel hemopoietin receptor protein, NR10

(19)

(11)

EP 2 325 316 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	19.04.2017 Bulletin 2017/16

(45)	Mention of the grant of the patent:
	07.09.2016 Bulletin 2016/36

(21)	Application number: 10180785.7

(22)	Date of filing: 01.06.2000

(51)

International Patent Classification (IPC):

C12N 15/12^(2006.01)
C07K 14/715^(2006.01)
C12P 21/02^(2006.01)
G01N 33/566^(2006.01)

C12N 5/10^(2006.01)
C07K 16/28^(2006.01)
G01N 33/53^(2006.01)

(54)	Novel hemopoietin receptor protein, NR10 Neues Hämopoietin Receptorprotein, NR10 Protéine réceptrice d'hémopoïétine, NR10

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30)

Priority:

02.06.1999 JP 15579799
30.07.1999 JP 21779799

(43)	Date of publication of application:
	25.05.2011 Bulletin 2011/21

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	09012659.0 / 2135953
	00931646.4 / 1188830

(73)	Proprietor: CHUGAI SEIYAKU KABUSHIKI KAISHA
	Tokyo, 115-8543 (JP)

(72)	Inventors:
	Maeda, Masatsugu Kamakura-shi Kanagawa 247-8530 (JP) Yaguchi, Noriko Kamakura-shi Kanagawa 247-8530 (JP)

(74)	Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB
	Siebertstrasse 3 81675 München 81675 München (DE)

(56)

References cited: :

EP-A- 0 411 946

WO-A2-95/33059

DATABASE EMBL [Online] 8 September 1998 (1998-09-08), "qa50c06.x1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:1690186 3', mRNA sequence.", XP002311247, retrieved from EBI accession no. EM_PRO:AI123586 Database accession no. AI123586
DATABASE EMBL [Online] 4 May 1996 (1996-05-04), "zb93e11.s1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone IMAGE:320396 3', mRNA sequence.", XP002311248, retrieved from EBI accession no. EM_PRO:W16834 Database accession no. W16834
HILTON D J ET AL: "CLONING AND CHARACTERIZATION OF A BINDING SUBUNIT OF THE INTERLEUKIN 13 RECEPTOR THAT IS ALSO A COMPONENT OF THE INTERLEUKIN4 RECEPTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 1, 9 January 1996 (1996-01-09), pages 497-501, XP002010896, ISSN: 0027-8424
GAINSFORD T ET AL: "LEPTIN CAN INDUCE PROLIFERATION DIFFERENTIATION AND FUNCTIONAL ACTIVATION OF HEMOPOIETIC CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, December 1996 (1996-12), pages 14564-14568, XP002921615, ISSN: 0027-8424
CIOFFI J A ET AL: "NOVEL B219/OB RECEPTOR ISOFORMS: POSSIBLE ROLE OF LEPTIN IN HEMATOPOIESIS AND REPRODUCTION", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 2, no. 5, May 1996 (1996-05), pages 585-589, XP002019361, ISSN: 1078-8956
HILTON D J ET AL: "CLONING OF A MURINE IL-11 RECEPTOR ALPHA-CHAIN; REQUIREMENT FOR GP130 FOR HIGH AFFINITY BINDING AND SIGNAL TRANSDUCTION", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 20, 17 October 1994 (1994-10-17), pages 4765-4775, XP000673205, ISSN: 0261-4189
ALEXANDER W S ET AL: "Suckling defect in mice lacking the soluble haemopoietin receptor NR6", CURRENT BIOLOGY, CURRENT SCIENCE,, GB, vol. 9, no. 11, 3 June 1999 (1999-06-03), pages 605-608, XP002155604, ISSN: 0960-9822

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).